Guidelines for the Pharmacotherapy of Schizophrenia in Adults
The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains. Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations ex...
Gespeichert in:
| Veröffentlicht in: | Canadian journal of psychiatry Jg. 62; H. 9; S. 604 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.09.2017
|
| Schlagworte: | |
| ISSN: | 1497-0015, 1497-0015 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains.
Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline.
Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines.
In most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia. |
|---|---|
| AbstractList | The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains.
Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline.
Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines.
In most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia. The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains.OBJECTIVEThe present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains.Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline.METHODGuidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline.Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines.RESULTSRecommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines.In most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia.CONCLUSIONSIn most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia. |
| Author | Addington, Donald Teehan, Michael Remington, Gary Ismail, Zahinoor Raedler, Thomas Honer, William |
| Author_xml | – sequence: 1 givenname: Gary surname: Remington fullname: Remington, Gary organization: 2 Schizophrenia Division, Continuing Care and Recovery Program, Centre for Addiction and Mental Health (CAMH), Toronto, Canada – sequence: 2 givenname: Donald surname: Addington fullname: Addington, Donald organization: 4 Hotchkiss Brain Institute and Matheson Centre for Mental Health Research and Education, Calgary, Canada – sequence: 3 givenname: William surname: Honer fullname: Honer, William organization: 5 Department of Psychiatry, University of British Columbia, Vancouver, Canada – sequence: 4 givenname: Zahinoor surname: Ismail fullname: Ismail, Zahinoor organization: 6 Department of Psychiatry, University of Calgary, Calgary, Canada – sequence: 5 givenname: Thomas surname: Raedler fullname: Raedler, Thomas organization: 7 Psychopharmacology Research Unit, Department of Psychiatry, University of Calgary, Calgary, Canada – sequence: 6 givenname: Michael surname: Teehan fullname: Teehan, Michael organization: 8 Department of Psychiatry, Dalhousie University, Halifax, Canada |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28703015$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEFLxDAUhIOsuLvVuyfJ0Uv1vTRt0oOHZdFVWFBQzyVtUhppm5q0h_XXW3EF5zIfw_DgzZosetcbQi4RbhCFuAUBmeCJmJkB5_KErJDnIgbAdPGPl2QdwgfMYkyekSWTApI5X5G73WS1aW1vAq2dp2Nj6EujfKcqN7NXw4G6mr5Wjf1yQ-NNbxW1Pd3oqR3DOTmtVRvMxdEj8v5w_7Z9jPfPu6ftZh9XKZNjjImuOedYcSwrjZBqrqXQRoKuU0CV5aWsSwUgeCZZWirMIMcMJedCCFmyiFz_3h28-5xMGIvOhsq0reqNm0KBOUrJ058ZInJ1rE5lZ3QxeNspfyj-Xmbf1yRYfQ |
| CitedBy_id | crossref_primary_10_1186_s13033_022_00529_8 crossref_primary_10_7759_cureus_53541 crossref_primary_10_3390_jcm13072073 crossref_primary_10_1080_13651501_2022_2151473 crossref_primary_10_1016_j_clinbiochem_2025_110957 crossref_primary_10_1186_s12991_020_00293_4 crossref_primary_10_1016_j_jchromb_2020_122499 crossref_primary_10_1038_s41398_020_0700_6 crossref_primary_10_1097_YIC_0000000000000442 crossref_primary_10_1503_jpn_200167 crossref_primary_10_1016_j_bbalip_2019_158534 crossref_primary_10_1016_j_bbadis_2024_167227 crossref_primary_10_1080_17425247_2020_1792439 crossref_primary_10_1093_schizbullopen_sgac058 crossref_primary_10_1111_acps_13411 crossref_primary_10_1177_20451253241280046 crossref_primary_10_1136_bmjopen_2021_055454 crossref_primary_10_1108_JMHTEP_03_2018_0019 crossref_primary_10_1002_npr2_12499 crossref_primary_10_1111_appy_70005 crossref_primary_10_1503_jpn_220223 crossref_primary_10_1016_j_schres_2020_12_002 crossref_primary_10_3389_fphar_2022_879224 crossref_primary_10_1016_j_schres_2022_03_006 crossref_primary_10_1007_s40263_023_01009_4 crossref_primary_10_1016_j_banm_2023_02_005 crossref_primary_10_1177_07067437221076723 crossref_primary_10_1097_MD_0000000000040897 crossref_primary_10_1177_2045125320982720 crossref_primary_10_1007_s00406_024_01938_1 crossref_primary_10_3390_medicina58111584 crossref_primary_10_1016_j_neubiorev_2022_104743 crossref_primary_10_1159_000499714 crossref_primary_10_1097_MD_0000000000032007 crossref_primary_10_1017_S0033291720000161 crossref_primary_10_1177_0706743717720197 crossref_primary_10_1111_eip_12868 crossref_primary_10_1080_14740338_2021_1910674 crossref_primary_10_5498_wjp_v13_i11_937 crossref_primary_10_1097_YIC_0000000000000417 crossref_primary_10_4103_indianjpsychiatry_indianjpsychiatry_702_21 crossref_primary_10_1002_npr2_12218 crossref_primary_10_1016_j_psycom_2022_100043 crossref_primary_10_3390_biom15050615 crossref_primary_10_3928_00485713_20180413_01 crossref_primary_10_1093_schbul_sbac203 crossref_primary_10_1007_s40263_023_01054_z crossref_primary_10_1186_s12888_024_06240_x crossref_primary_10_1016_j_schres_2019_10_049 crossref_primary_10_1038_s41537_022_00211_5 crossref_primary_10_1016_j_psychres_2019_02_050 crossref_primary_10_1016_j_schres_2024_06_001 crossref_primary_10_1080_14656566_2021_2023496 crossref_primary_10_1097_YIC_0000000000000404 crossref_primary_10_3389_fendo_2021_609240 crossref_primary_10_1093_ijnp_pyaf011 crossref_primary_10_1177_0269881119889296 crossref_primary_10_1080_15622975_2024_2367138 crossref_primary_10_1177_0706743717739549 crossref_primary_10_1007_s00406_024_01798_9 crossref_primary_10_1097_JCP_0000000000001816 crossref_primary_10_1093_schizbullopen_sgab048 crossref_primary_10_1124_pharmrev_122_000788 crossref_primary_10_1016_j_schres_2018_02_058 crossref_primary_10_1038_s41537_021_00192_x crossref_primary_10_1177_20451253231158152 crossref_primary_10_1016_j_schres_2024_01_035 crossref_primary_10_3390_brainsci13040651 crossref_primary_10_1080_01612840_2023_2229435 crossref_primary_10_1016_j_bbr_2021_113507 crossref_primary_10_1097_MD_0000000000039629 crossref_primary_10_1038_s41380_020_0704_x crossref_primary_10_1016_j_schres_2023_10_001 crossref_primary_10_1007_s40263_018_0565_x crossref_primary_10_1097_JCP_0000000000001348 crossref_primary_10_1177_07067437241261928 crossref_primary_10_1097_YCO_0000000000000403 crossref_primary_10_3389_fpsyt_2019_00210 crossref_primary_10_2147_NDT_S548538 crossref_primary_10_1016_j_schres_2018_11_015 crossref_primary_10_1111_bcpt_13867 crossref_primary_10_1016_j_euroneuro_2021_10_448 crossref_primary_10_1177_20451253221112587 crossref_primary_10_1176_appi_ajp_2020_20071120 crossref_primary_10_1016_j_brs_2022_08_012 crossref_primary_10_1097_CXA_0000000000000068 crossref_primary_10_1016_j_schres_2024_01_021 crossref_primary_10_1111_pcn_13578 crossref_primary_10_1192_j_eurpsy_2021_23 crossref_primary_10_1002_pcn5_13 crossref_primary_10_3390_pharmacy9030123 crossref_primary_10_1016_j_schres_2022_02_019 crossref_primary_10_1177_0269881120909416 crossref_primary_10_3389_fpsyt_2024_1474626 crossref_primary_10_1176_appi_ajp_20250068 crossref_primary_10_1017_S1092852922000967 crossref_primary_10_1177_07067437211055413 crossref_primary_10_1177_07067437241293983 crossref_primary_10_3389_fphar_2023_1080073 crossref_primary_10_3389_fphar_2021_638001 crossref_primary_10_1017_S204579602200066X crossref_primary_10_12688_f1000research_166156_1 crossref_primary_10_3389_fphar_2023_1260915 crossref_primary_10_1016_j_ajp_2024_104047 crossref_primary_10_1016_j_mehy_2021_110506 crossref_primary_10_1016_j_euroneuro_2021_10_439 crossref_primary_10_1016_j_psychres_2024_116256 crossref_primary_10_1111_pcn_12911 crossref_primary_10_1016_j_conctc_2024_101337 crossref_primary_10_1192_bjo_2021_982 crossref_primary_10_1192_j_eurpsy_2024_5 crossref_primary_10_1177_0706743718772522 crossref_primary_10_1192_bjo_2022_44 crossref_primary_10_1111_acps_13801 crossref_primary_10_1016_j_encep_2021_02_008 crossref_primary_10_3389_fpsyt_2021_723245 crossref_primary_10_3390_jcm11175040 crossref_primary_10_1016_j_jpsychires_2024_01_020 crossref_primary_10_1080_15622975_2021_2011403 crossref_primary_10_3389_fpsyt_2025_1537418 crossref_primary_10_7759_cureus_63871 crossref_primary_10_1155_2021_8403986 crossref_primary_10_1186_s12888_022_03914_2 crossref_primary_10_1080_00207411_2024_2368286 crossref_primary_10_1080_14656566_2022_2102421 crossref_primary_10_1186_s12888_025_07165_9 crossref_primary_10_1089_jchc_23_10_0089 crossref_primary_10_1007_s40801_023_00376_0 crossref_primary_10_1016_j_bbr_2021_113126 crossref_primary_10_1177_00048674211025696 crossref_primary_10_3389_fpsyt_2019_00842 crossref_primary_10_1111_eip_12685 crossref_primary_10_2174_1874467215666220211094910 crossref_primary_10_3389_fphar_2019_01612 crossref_primary_10_1016_j_beth_2024_05_001 crossref_primary_10_1016_j_schres_2023_11_008 crossref_primary_10_1002_glia_24221 crossref_primary_10_1093_ijnp_pyac036 crossref_primary_10_1097_JCP_0000000000001548 crossref_primary_10_1016_j_yebeh_2022_108911 crossref_primary_10_1007_s40265_019_1052_5 crossref_primary_10_1016_j_bbih_2024_100923 crossref_primary_10_3390_ph18030369 crossref_primary_10_1016_j_ajp_2019_02_005 crossref_primary_10_3390_biomedicines11072088 crossref_primary_10_3390_brainsci14080791 crossref_primary_10_1186_s12888_022_04075_y crossref_primary_10_1080_03639045_2021_1934859 crossref_primary_10_1007_s11096_022_01426_3 crossref_primary_10_1007_s40501_019_00173_z crossref_primary_10_1176_appi_ajp_2020_19121279 crossref_primary_10_1038_s41598_021_92731_w crossref_primary_10_1080_09540261_2023_2287095 crossref_primary_10_1007_s00739_024_01000_8 crossref_primary_10_1007_s40801_025_00511_z crossref_primary_10_1038_s41537_020_00130_3 crossref_primary_10_3390_nu14235142 crossref_primary_10_1016_j_metabol_2022_155335 crossref_primary_10_12688_wellcomeopenres_18028_1 crossref_primary_10_12688_wellcomeopenres_18028_2 crossref_primary_10_2478_amb_2021_0023 crossref_primary_10_1016_j_psychres_2020_112890 crossref_primary_10_1016_j_schres_2021_07_040 crossref_primary_10_3389_fpsyt_2022_1071079 crossref_primary_10_5812_ijpbs_133703 crossref_primary_10_1111_eip_13202 crossref_primary_10_1016_j_jad_2024_02_038 crossref_primary_10_1007_s00406_018_0908_0 crossref_primary_10_1177_07067437241290181 crossref_primary_10_1016_j_ajp_2025_104597 crossref_primary_10_1080_14740338_2024_2328812 crossref_primary_10_1016_j_psychres_2025_116684 crossref_primary_10_1016_j_psyneuen_2021_105257 crossref_primary_10_1007_s40263_025_01206_3 crossref_primary_10_1097_JCP_0000000000001416 crossref_primary_10_1016_j_clinthera_2025_07_001 crossref_primary_10_1177_20451253231157219 crossref_primary_10_1016_j_schres_2020_11_010 crossref_primary_10_1080_14737167_2020_1758558 crossref_primary_10_1089_tmj_2021_0122 crossref_primary_10_3389_fpsyt_2022_796719 crossref_primary_10_1097_JCP_0000000000001062 crossref_primary_10_1038_s41537_021_00158_z crossref_primary_10_1016_j_schres_2021_07_024 crossref_primary_10_1080_09540261_2019_1613965 crossref_primary_10_3389_fpsyt_2023_1123246 crossref_primary_10_1016_j_pmip_2019_02_001 crossref_primary_10_1016_j_schres_2019_09_013 crossref_primary_10_52667_2712_9179_2025_5_2_37_48 crossref_primary_10_1016_j_schres_2019_05_030 crossref_primary_10_1371_journal_pone_0241986 crossref_primary_10_1016_j_ajp_2018_12_011 crossref_primary_10_2147_NDT_S374696 crossref_primary_10_1159_000494695 crossref_primary_10_1016_j_biopha_2024_116236 crossref_primary_10_1016_j_psychres_2023_115575 crossref_primary_10_1080_17522439_2022_2134444 crossref_primary_10_1016_j_ejphar_2024_176821 crossref_primary_10_3389_fpsyt_2022_917361 crossref_primary_10_1139_facets_2020_0082 crossref_primary_10_1093_ijnp_pyac002 crossref_primary_10_1002_phar_4649 crossref_primary_10_2147_NDT_S390482 crossref_primary_10_1192_bja_2020_57 crossref_primary_10_1016_j_ajp_2021_102917 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1177/0706743717720448 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1497-0015 |
| ExternalDocumentID | 28703015 |
| Genre | Systematic Review Journal Article |
| GroupedDBID | --- -TM .55 .GJ 0R~ 29B 2WC 36B 53G 54M 5GY 5RE 5WV 6PF 7X7 88E 8AO 8FI 8FJ 8FQ 8G5 8R4 8R5 96U AABMB AACMV AADUE AAEJI AAEWN AAGGD AAITX AAKGS AANSI AAOVH AAPEO AAPII AAQXH AAQXI AARDL AARIX AATAA AAUAS AAUPJ AAWTL AAXOT AAYJJ AAZBJ ABAWC ABAWP ABCCA ABCJG ABDWY ABEIX ABFNE ABFWQ ABHKI ABIDT ABJNI ABJZC ABKRH ABLUO ABPGX ABPNF ABQKF ABQXT ABRHV ABUJY ABUWG ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACGBL ACGFO ACGFS ACIHN ACJER ACJTF ACLFY ACLHI ACOFE ACOXC ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADEBD ADEIA ADGDL ADMPF ADRRZ ADTBJ ADUKL ADVBO ADZYD ADZZY AEAQA AECGH AEPTA AEQLS AESZF AEWDL AEWHI AEXFG AEXNY AFAZI AFEET AFFNX AFGYO AFKRA AFKRG AFMOU AFQAA AFUIA AGHKR AGKLV AGNHF AGPXR AGWFA AHDMH AHMBA AI. AIGRN AIIQI AJABX AJEFB AJGYC AJMMQ AJUZI AJVBE AJXAJ ALEEW ALIPV ALKWR ALMA_UNASSIGNED_HOLDINGS AMCVQ ANDLU AOIJS ARTOV AUTPY AYAKG AZQEC B8M BBRGL BCR BDDNI BENPR BKIIM BKSCU BLC BPACV BPHCQ BVXVI BWJAD C1A CBRKF CCPQU CDWPY CFDXU CGR CORYS CQQTX CUTAK CUY CVF DC- DC. DOPDO DV7 DWQXO E3Z EAU EBS ECM ECV EIF EJD EMOBN F5P F8P FHBDP FYUFA GNUQQ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION GUQSH H13 HMCUK HYE H~9 J8X K.F KQ8 M1P M2M M2O M3G N4W NPM O9- OK1 P2P P6G PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ Q1R Q2X ROL RPM SAUOL SCNPE SFC SHG SPQ SPV TR2 U5U UKHRP UPT VH1 WH7 X7M XJT XSB YR5 YYQ ZCG ZGI ZONMY ZPPRI ZRKOI ZSSAH ZXP ~34 7X8 AJHME |
| ID | FETCH-LOGICAL-c528t-13df4441c41bcd105d4d87de80df501a69b8fba00746825ba16091618447778b2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 250 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000411068200003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1497-0015 |
| IngestDate | Sun Nov 09 14:06:11 EST 2025 Mon Jul 21 05:23:14 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | antipsychotics clinical practice guideline adult psychiatry schizophrenia systematic review pharmacotherapy |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c528t-13df4441c41bcd105d4d87de80df501a69b8fba00746825ba16091618447778b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| OpenAccessLink | https://journals.sagepub.com/doi/pdf/10.1177/0706743717720448 |
| PMID | 28703015 |
| PQID | 1918845177 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1918845177 pubmed_primary_28703015 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-09-01 |
| PublicationDateYYYYMMDD | 2017-09-01 |
| PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Canadian journal of psychiatry |
| PublicationTitleAlternate | Can J Psychiatry |
| PublicationYear | 2017 |
| SSID | ssj0000228 |
| Score | 2.6109369 |
| SecondaryResourceType | review_article |
| Snippet | The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains.
Guidelines were developed... The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains.OBJECTIVEThe present... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 604 |
| SubjectTerms | Adult Antipsychotic Agents - therapeutic use Canada Evidence-Based Medicine - standards Humans Practice Guidelines as Topic - standards Schizophrenia - drug therapy |
| Title | Guidelines for the Pharmacotherapy of Schizophrenia in Adults |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28703015 https://www.proquest.com/docview/1918845177 |
| Volume | 62 |
| WOSCitedRecordID | wos000411068200003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEB7Uinjx_agvInhd2t1kN-lBpIjVgy0FH_S2bDYJ9LJbXSv4753JbqkXQfCytw1hMpl8k5l8H8AV57yXY3ocOOt4IKRJcM-5LEjQn5Kejrj1ZM-vj3I0UpNJb9xcuFVNW-UiJvpAbcqc7sg7mFcoJeJQypvZW0CqUVRdbSQ0VqHFEcqQV8vJki2cuF386yJiHMVzb1mm7KCnU_s9JjOk0iLU7wDTHzSD7f9OcQe2GojJ-rVP7MKKLfZgY9gU0ffh-n5O3FbU784QsjKEgGzcMFjXz7G-WOnY0892PDYtWJ-oOqoDeBncPd8-BI2KQpDHkSKteeMEgp5chDo3CKeMMEoaq7rGxd0wwxVRTmdeeATTRZ2FCWII0oERUkqlo0NYK8rCHgNLJBrR4FgCR4yjBGNjqBIuteaWCqBtuFwYJkUvpdJDVthyXqVL07ThqLZuOqvpNFIqtWKYiU_-8PcpbEZ0rvomrzNoOdyj9hzW88-PafV-4Zcfv6Px8BtORLZ_ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Guidelines+for+the+Pharmacotherapy+of+Schizophrenia+in+Adults&rft.jtitle=Canadian+journal+of+psychiatry&rft.au=Remington%2C+Gary&rft.au=Addington%2C+Donald&rft.au=Honer%2C+William&rft.au=Ismail%2C+Zahinoor&rft.date=2017-09-01&rft.eissn=1497-0015&rft.volume=62&rft.issue=9&rft.spage=604&rft_id=info:doi/10.1177%2F0706743717720448&rft_id=info%3Apmid%2F28703015&rft_id=info%3Apmid%2F28703015&rft.externalDocID=28703015 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1497-0015&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1497-0015&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1497-0015&client=summon |